Cerebrolysin is under clinical development by EVER Neuro Pharma and currently in Phase II for Unspecified Neurologic Disorders. According to GlobalData, Phase II drugs for Unspecified Neurologic Disorders does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Cerebrolysin LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cerebrolysin overview
Cerebrolysin is a porcine brain-derived peptide and a neuro protective agent. It is formulated as solution for intravenous and intramuscular route of administration. Cerebrolysin is indicated for the treatment of ischemic and hemorrhagic stroke, traumatic brain injuries (TBI), different forms of dementia (vascular dementia, Alzheimer’s disease) and cognitive disorders and to prevent cognitive decline after brain injuries, chronic cerebrovascular insufficiency, attention deficit disorders in children, and endogenous depression resistant to antidepressants (as part of complex therapy).
Cerebrolysin is under development for the treatment of posterior circulation stroke secondary to basilar artery occlusion, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Cerebrolysin was also under development for the treatment of frontotemporal dementia. The drug candidate is formulated as a solution for the intravenous and intramuscular route of administration.
EVER Neuro Pharma overview
EVER Neuro Pharma (EVER Pharma) is a pharmaceuticals company. It focuses on the research, development, production and commercialization of products in the areas of neurology and specialty injectables, covering oncology, intensive care and hormone therapeutics. The company offers oxytocin, paclitaxel, pemetrexed, terlipressin, testosterone undecanoate, trabectedin, dexmedetomidine, docetaxel, fulvestrant, atosiban, bortezomib, cabazitaxel and others. It provides services such as from development through commercial contract manufacturing. The company operates manufacturing facilities in Austria and Germany. EVER Pharma is headquartered in Unterach, Austria.
For a complete picture of Cerebrolysin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
